Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 336-346 , March 2008

Residual γH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy

  • Peggy L. Olive

      Affiliations

    • Medical Biophysics Department, British Columbia Cancer Research Centre, BC, Canada
    • Corresponding Author InformationCorresponding author. Peggy L. Olive, Head, Medical Biophysics Department, British Columbia Cancer Research Centre, 675 W. 10th Avenue, Vancouver, BC, Canada V5Z 1L3.
    • ,
  • Judit P. Banáth

      Affiliations

    • Medical Biophysics Department, British Columbia Cancer Research Centre, BC, Canada
    • ,
  • Mira Keyes

      Affiliations

    • Radiation Oncology Prostate Brachytherapy Program, British Columbia Cancer Agency, BC, Canada

Received 31 May 2007 ,Revised 31 August 2007 ,Accepted 8 September 2007.

References 

  1. Banath JP, MacPhail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 2004;64:7144–7149
  2. Bassing CH, Chua KF, Sekiguchi J, et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA. 2002;99:8173–8178
  3. Brock WA, Tucker SL, Geara FB, et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys. 1995;32:1371–1379
  4. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:196–202
  5. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ. 2003;168:31–35
  6. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006;12:2545–2554
  7. Dikomey E, Borgmann K, Peacock J, Jung H. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys. 2003;56:1194–1200
  8. Gorbunova V, Seluanov A. Making ends meet in old age: DSB repair and aging. Mech Ageing Dev. 2005;126:621–628
  9. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  10. Hamasaki K, Imai K, Nakachi K, Takahashi N, Kodama Y, Kusunoki Y. Short-term culture and gammaH2AX flow cytometry determine differences in individual radiosensitivity in human peripheral T lymphocytes. Environ Mol Mutagen. 2007;48:38–47
  11. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol. 1996;40:101–109
  12. Kato TA, Nagasawa H, Weil MM, Genik PC, Little JB, Bedford JS. gamma-H2AX foci after low-dose-rate irradiation reveal atm haploinsufficiency in mice. Radiat Res. 2006;166:47–54
  13. Kato TA, Nagasawa H, Weil MM, Little JB, Bedford JS. Levels of gamma-H2AX Foci after low-dose-rate irradiation reveal a DNA DSB rejoining defect in cells from human ATM heterozygotes in two at families and in another apparently normal individual. Radiat Res. 2006;166:443–453
  14. Keyes M, Miller S, Moravan V, et al. Acute and late urinary toxicity in 606 prostate brachytherapy patients – the BCCA experience. Radiother Oncol. 2006;80:S41–S42
  15. Keyes M, Morvan V, Liu M, Jankovic B, Morris WJ. Rectal toxicity after prostate brachytherapy. Radiother Oncol. 2005;76:S5–S6
  16. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?. Int J Radiat Oncol Biol Phys. 2006;64:825–834
  17. Klokov D, Macphail SM, Banath JP, Byrne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol. 2006;80:223–229
  18. Kuhne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, Lobrich M. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res. 2004;64:500–508
  19. Kurose A, Tanaka T, Huang X, et al. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A. 2005;68:1–9
  20. Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569:123–132
  21. Lobrich M, Kiefer J. Assessing the likelihood of severe side effects in radiotherapy. Int J Cancer. 2006;118:2652–2656
  22. Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys. 2005;63:155–163
  23. MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 2003;79:351–358
  24. MacPhail SH, Banath JP, Yu Y, Chu E, Olive PL. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G(1)-phase cells. Radiat Res. 2003;159:759–767
  25. Mahrhofer H, Burger S, Oppitz U, Flentje M, Djuzenova CS. Radiation induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys. 2006;64:573–580
  26. Marchetti F, Coleman MA, Jones IM, Wyrobek AJ. Candidate protein biodosimeters of human exposure to ionizing radiation. Int J Radiat Biol. 2006;82:605–639
  27. Mayer PJ, Lange CS, Bradley MO, Nichols WW. Age-dependent decline in rejoining of X-ray-induced DNA double-strand breaks in normal human lymphocytes. Mutat Res. 1989;219:95–100
  28. Mei N, Imada H, Nomoto S, Kunugita N, Norimura T. Individual variation and age dependency in the radiosensitivity of peripheral blood T-lymphocytes from normal donors. J Radiat Res (Tokyo). 1996;37:235–245
  29. Mirzayans R, Severin D, Murray D. Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity. Int J Radiat Oncol Biol Phys. 2006;66:1498–1505
  30. Morrison AJ, Shen X. DNA repair in the context of chromatin. Cell Cycle. 2005;4:568–571
  31. Nag S, Ellis RJ, Merrick GS, Bahnson R, Wallner K, Stock R. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54:462–470
  32. Nakamura N, Sposto R, Kushiro J, Akiyama M. Is interindividual variation of cellular radiosensitivity real or artifactual?. Radiat Res. 1991;125:326–330
  33. Pickles T. Current status of PSA screening. Early detection of prostate cancer. Can Fam Physician. 2004;50:57–63
  34. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  35. Ramsey MJ, Moore DH, Briner JF, et al. The effects of age and lifestyle factors on the accumulation of cytogenetic damage as measured by chromosome painting. Mutat Res. 1995;338:95–106
  36. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks In vivo. J Cell Biol. 1999;146:905–916
  37. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. 2000;275:9390–9395
  38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–5868
  39. Rudat V, Dietz A, Nollert J, et al. Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol. 1999;53:233–245
  40. Russell NS, Begg AC. Editorial radiotherapy and oncology 2002: predictive assays for normal tissue damage. Radiother Oncol. 2002;64:125–129
  41. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose–volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  42. Stock RG, Stone NN, Dahlal M, Lo YC. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  43. Stone NN, Stock RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy. 2003;2:32–39
  44. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5years. Urology. 2007;69:338–342
  45. Svensson JP, Stalpers LJ, Esveldt-van Lange RE, et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med. 2006;3:e422
  46. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316:1289–1294
  47. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279:2273–2280
  48. Van Gellekom MP, Moerland MA, Van VM, Wijrdeman HK, Battermann JJ. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys. 2005;63:772–780
  49. Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:342–353
  50. West CM, Davidson SE, Elyan SA, et al. Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2001;51:10–15
  51. Wykes SM, Piasentin E, Joiner MC, Wilson GD, Marples B. Low-dose hyper-radiosensitivity is not caused by a failure to recognize DNA double-strand breaks. Radiat Res. 2006;165:516–524

PII: S0167-8140(07)00455-0

doi: 10.1016/j.radonc.2007.09.002

Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 336-346 , March 2008

Article Tools

* Image Usage & Resolution